Market Overview

AtriCure Sees Q4 Sales ~$18.4M

Related ATRC
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Rank #5 Additions for Tuesday - Tale of the Tape

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, in anticipation of investor meetings in San Francisco during the week of January 7, is announcing preliminary financial results for fourth quarter and full year 2012.

Preliminary revenue for the fourth quarter of 2012 is expected to be approximately $18.4 million, reflecting growth of approximately 9.5% over the fourth quarter of 2011. Based on these preliminary estimates, revenue from U.S. customers is expected to be $13.7 million, reflecting growth of 10.2%, and revenue from international customers is expected to be $4.7 million, reflecting growth of 7.7%, or 10.0% on a constant currency basis.

Preliminary revenue for full year 2012 is expected to be $70.2 million, reflecting year over year growth of 9.1% over full year 2011.

Posted-In: News Guidance

 

Most Popular

Related Articles (ATRC)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free